Poseida Therapeutics, a San Diego, California-based biopharmaceutical company developing cell therapies, has appointed Martin Giedlin, PhD, as vice president, technical operations.

Giedlin has experience in cell-therapy process development, manufacturing, and strategy in immunotherapies. Most recently, he led the process development teams that generated the clinical and commercial manufacturing process in support of Novartis’ Kymriah (tisagenlecleucel), a chimeric antigen receptor T-cell (CAR-T) therapy, the first CAR-T therapy approved by the US Food and Drug Administration.

Giedlin brings more than 20 years of experience supporting immunotherapy options for cancer and infectious disease through developing recombinant proteins, monoclonal antibodies, gene therapies, and vaccines. He most recently served as executive director, process sciences, in Novartis Pharmaceuticals’ Cell and Gene Therapy Group that focused on gene-editing of autologous T cells. He also served as vice president, development, at Sangamo, a Richmond, California-based biotechnology company, which uses zinc-fingered proteins for both cellular and vector-mediated gene-editing to generate therapies for treating genetic and infectious disease. Prior to that he served as senior director, in vivo biology, at Cerus Corporation, a Concord, California-headquartered biomedical products company, and Onyx Pharmaceuticals, a South San Francisco, California-based biopharmaceutical company and Amgen subsidiary.

Source: Poseida Therapeutics